Mahmoud A AbdelRazek1, Jose Gutierrez1, David Mampre1, Anna Cervantes-Arslanian1, Cora Ormseth1, Diogo Haussen1, Kiran T Thakur1, Jennifer L Lyons1, Bryan R Smith1, Owen O'Connor1, Joshua Z Willey1, Farrah J Mateen2. 1. From the Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (M.A.A., O.O., F.J.M.); Department of Neurology, Columbia University Medical Center, New York, NY (J.G., K.T.T., J.Z.W.); Department of Neurology, Yale-New Haven Hospital, CT (D.M., C.O.); Department of Neurology, Boston University School of Medicine, MA (A.C.-A.); Department of Neurology, University of Miami Hospital, FL (D.H.); Department of Neurology, Brigham and Women's Hospital-Harvard Medical School, Boston, MA (J.L.L.); and Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, Bethesda, MD (B.R.S.). 2. From the Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (M.A.A., O.O., F.J.M.); Department of Neurology, Columbia University Medical Center, New York, NY (J.G., K.T.T., J.Z.W.); Department of Neurology, Yale-New Haven Hospital, CT (D.M., C.O.); Department of Neurology, Boston University School of Medicine, MA (A.C.-A.); Department of Neurology, University of Miami Hospital, FL (D.H.); Department of Neurology, Brigham and Women's Hospital-Harvard Medical School, Boston, MA (J.L.L.); and Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, Bethesda, MD (B.R.S.). fmateen@partners.org.
Abstract
BACKGROUND AND PURPOSE: Human immunodeficiency virus (HIV) infection has been shown to increase both ischemic and hemorrhagic stroke risks, but there are limited data on the safety and outcomes of intravenous thrombolysis with tPA (tissue-type plasminogen activator) for acute ischemic stroke in HIV-infected patients. METHODS: A retrospective chart review of intravenous tPA-treated HIV patients who presented with acute stroke symptoms was performed in 7 large inner-city US academic centers (various search years between 2000 and 2017). We collected data on HIV, National Institutes of Health Stroke Scale score, ischemic stroke risk factors, opportunistic infections, intravenous drug abuse, neuroimaging findings, and modified Rankin Scale score at last follow-up. RESULTS: We identified 33 HIV-infected patients treated with intravenous tPA (mean age, 51 years; 24 men), 10 of whom were stroke mimics. Sixteen of 33 (48%) patients had an HIV viral load less than the limit of detection while 10 of 33 (30%) had a CD4 count <200/mm3. The median National Institutes of Health Stroke Scale score at presentation was 9, and mean time from symptom onset to tPA was 144 minutes (median, 159). The median modified Rankin Scale score for the 33-patient cohort was 1 and for the 23-patient actual stroke cohort was 2, measured at a median of 90 days poststroke symptom onset. Two patients had nonfatal hemorrhagic transformation (6%; 95% confidence interval, 1%-20%), both in the actual stroke group. Two patients had varicella zoster virus vasculitis of the central nervous system, 1 had meningovascular syphilis, and 7 other patients were actively using intravenous drugs (3 cocaine, 1 heroin, and 3 unspecified), none of whom had hemorrhagic transformation. CONCLUSIONS: Most HIV-infected patients treated with intravenous tPA for presumed and actual acute ischemic stroke had no complications, and we observed no fatalities. Stroke mimics were common, and thrombolysis seems safe in this group. We found no data to suggest an increased risk of intravenous tPA-related complications because of concomitant opportunistic infections or intravenous drug abuse.
BACKGROUND AND PURPOSE:Human immunodeficiency virus (HIV) infection has been shown to increase both ischemic and hemorrhagic stroke risks, but there are limited data on the safety and outcomes of intravenous thrombolysis with tPA (tissue-type plasminogen activator) for acute ischemic stroke in HIV-infectedpatients. METHODS: A retrospective chart review of intravenous tPA-treated HIVpatients who presented with acute stroke symptoms was performed in 7 large inner-city US academic centers (various search years between 2000 and 2017). We collected data on HIV, National Institutes of Health Stroke Scale score, ischemic stroke risk factors, opportunistic infections, intravenous drug abuse, neuroimaging findings, and modified Rankin Scale score at last follow-up. RESULTS: We identified 33 HIV-infectedpatients treated with intravenous tPA (mean age, 51 years; 24 men), 10 of whom were stroke mimics. Sixteen of 33 (48%) patients had an HIV viral load less than the limit of detection while 10 of 33 (30%) had a CD4 count <200/mm3. The median National Institutes of Health Stroke Scale score at presentation was 9, and mean time from symptom onset to tPA was 144 minutes (median, 159). The median modified Rankin Scale score for the 33-patient cohort was 1 and for the 23-patientactual stroke cohort was 2, measured at a median of 90 days poststroke symptom onset. Two patients had nonfatal hemorrhagic transformation (6%; 95% confidence interval, 1%-20%), both in the actual stroke group. Two patients had varicella zoster virus vasculitis of the central nervous system, 1 had meningovascular syphilis, and 7 other patients were actively using intravenous drugs (3 cocaine, 1 heroin, and 3 unspecified), none of whom had hemorrhagic transformation. CONCLUSIONS: Most HIV-infectedpatients treated with intravenous tPA for presumed and actual acute ischemic stroke had no complications, and we observed no fatalities. Stroke mimics were common, and thrombolysis seems safe in this group. We found no data to suggest an increased risk of intravenous tPA-related complications because of concomitant opportunistic infections or intravenous drug abuse.
Authors: Ville Artto; Jukka Putaala; Daniel Strbian; Atte Meretoja; Katja Piironen; Ron Liebkind; Heli Silvennoinen; Sari Atula; Olli Häppölä Journal: Ann Emerg Med Date: 2011-10-14 Impact factor: 5.721
Authors: E M Sweeney; K T Thakur; J L Lyons; B R Smith; J Z Willey; A M Cervantes-Arslanian; M K Hickey; K Uchino; D C Haussen; S Koch; L H Schwamm; M S V Elkind; R T Shinohara; F J Mateen Journal: Eur J Neurol Date: 2014-07-10 Impact factor: 6.089
Authors: Julia L Marcus; Wendy A Leyden; Chun R Chao; Felicia C Chow; Michael A Horberg; Leo B Hurley; Daniel B Klein; Charles P Quesenberry; William J Towner; Michael J Silverberg Journal: AIDS Date: 2014-08-24 Impact factor: 4.177
Authors: Farrah J Mateen; Russell T Shinohara; Marco Carone; Eric N Miller; Justin C McArthur; Lisa P Jacobson; Ned Sacktor Journal: Neurology Date: 2012-10-17 Impact factor: 9.910
Authors: Réza Behrouz; Christopher Hans Topel; Ali Seifi; Lee A Birnbaum; Robin L Brey; Vivek Misra; Mario Di Napoli Journal: J Neurovirol Date: 2016-04-04 Impact factor: 2.643
Authors: Kaku So-Armah; Laura A Benjamin; Gerald S Bloomfield; Matthew J Feinstein; Priscilla Hsue; Benson Njuguna; Matthew S Freiberg Journal: Lancet HIV Date: 2020-04 Impact factor: 16.070